Enliven Therapeutics ELVN Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's change in accrued liabilities?
- Enliven Therapeutics (ELVN) reported change in accrued liabilities of -$4.47M in Q1 2026.
- How has Enliven Therapeutics's change in accrued liabilities changed year-over-year?
- Enliven Therapeutics's change in accrued liabilities decreased by 79.0% year-over-year, from -$2.5M to -$4.47M.
- What is the long-term trend for Enliven Therapeutics's change in accrued liabilities?
- Over 3 years (2021 to 2024), Enliven Therapeutics's change in accrued liabilities has grown at a -14.2% compound annual growth rate (CAGR), from $393K to -$248K.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.